Related Experiment Video

Updated: Sep 30, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis

Sreesatya Raju Vulapalli1, Zhongyi Chen, Balvin H L Chua

  • 1Cardiology Unit, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA. raju_vulapalli@urmc.rochester.edu

American Journal of Physiology. Heart and Circulatory Physiology
|July 19, 2002
PubMed

Insights

Heme oxygenase-1 (HO-1) overexpression in the heart protects against ischemia-reperfusion injury. This cardioprotective effect in mice is linked to reduced cardiomyocyte apoptosis.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cellular Physiology

Background:

  • Heme oxygenase (HO)-1 is an enzyme involved in heme metabolism.
  • Prior research suggests a cardioprotective role for HO-1 in heart failure.
  • Investigating HO-1's role in preventing cardiomyocyte apoptosis and cardiac dysfunction is crucial.

Purpose of the Study:

  • To determine if HO-1 prevents cardiomyocyte apoptosis and cardiac dysfunction following ischemia-reperfusion (I/R) injury.
  • To assess the cardioprotective effects of HO-1 overexpression in the heart.

Main Methods:

  • Generated transgenic mice with cardiac-specific HO-1 overexpression using the alpha-myosin heavy chain promoter.
  • Utilized isolated heart preparations to evaluate functional recovery after ischemia-reperfusion.
  • Assessed I/R injury in intact animals via coronary ligation and reperfusion.
  • Quantified cardiomyocyte apoptosis using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling and in situ oligo ligation.

Main Results:

  • HO-1 transcript and protein levels were significantly elevated in the hearts of transgenic mice.
  • Transgenic hearts demonstrated enhanced functional recovery during reperfusion compared to controls.
  • HO-1 overexpression significantly reduced cardiac apoptosis in mice subjected to I/R injury.
  • Fewer apoptotic myocytes were observed in HO-1 overexpressing hearts.

Conclusions:

  • Cardioselective overexpression of HO-1 confers a protective effect against myocardial I/R injury in mice.
  • The cardioprotective mechanism of HO-1 likely involves an antiapoptotic action.
  • HO-1 plays a significant role in mitigating cardiac damage during ischemic events.

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...